Akari Therapeutics Plc

For the period ended Dec 31, 2023. Filed Mar 29, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 29, 2024

AKTX$7.13-6.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets at December 31, 2023 and 2022

Consolidated Balance Sheets

as of December 31, 2023 and 2022

	December 31,	December 31,
(In thousands, except share and per share amounts)	2023	2022
ASSETS
Current assets:
Cash	$3,845	$13,250
Prepaid expenses	299	465
Other current assets	197	100
Total current assets	4,341	13,815
Patent acquisition costs, net	14	17
Total assets	$4,355	$13,832
LIABILITIES AND SHAREHOLDERS’ (DEFICIT) EQUITY
Current liabilities:
Accounts payable	$1,671	$947
Accrued expenses	1,566	3,148
Warrant liability	1,253	7,852
Other current liability	94	94
Total liabilities	4,584	12,041
Commitments and contingencies (Note 8)
Shareholders’ (deficit) equity:
Share capital of $0.0001 par value
Authorized: 45,122,321,523 and 15,000,000,000 ordinary shares at December 31, 2023 and 2022, respectively; issued and outstanding: 13,234,315,298 and 7,444,917,123 at December 31, 2023 and 2022, respectively	1,324	745
Additional paid-in capital	174,754	167,076
Capital redemption reserve	52,194	52,194
Accumulated other comprehensive loss	(1,040)	(771)
Accumulated deficit	(227,461)	(217,453)
Total shareholders’ (deficit) equity	(229)	1,791
Total liabilities and shareholders' (deficit) equity	$4,355	$13,832

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.